Marquette Asset Management LLC Takes Position in Johnson & Johnson (NYSE:JNJ)

Marquette Asset Management LLC acquired a new stake in Johnson & Johnson (NYSE:JNJ) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 1,680 shares of the company’s stock, valued at approximately $272,000.

A number of other institutional investors have also made changes to their positions in the company. Bellevue Group AG increased its stake in shares of Johnson & Johnson by 23.9% in the fourth quarter. Bellevue Group AG now owns 28,280 shares of the company’s stock worth $4,433,000 after buying an additional 5,457 shares during the last quarter. Icon Wealth Advisors LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $1,392,000. Putnam Investments LLC grew its stake in Johnson & Johnson by 0.3% in the fourth quarter. Putnam Investments LLC now owns 624,978 shares of the company’s stock worth $97,959,000 after purchasing an additional 2,128 shares in the last quarter. Caxton Associates LP raised its stake in Johnson & Johnson by 199.4% during the fourth quarter. Caxton Associates LP now owns 18,341 shares of the company’s stock valued at $2,875,000 after buying an additional 12,216 shares in the last quarter. Finally, First Financial Bankshares Inc bought a new position in Johnson & Johnson during the 4th quarter worth approximately $78,509,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.1 %

Shares of Johnson & Johnson stock opened at $159.64 on Wednesday. The business has a fifty day simple moving average of $162.62 and a 200-day simple moving average of $154.33. The firm has a market cap of $384.20 billion, a price-to-earnings ratio of 9.95, a price-to-earnings-growth ratio of 2.69 and a beta of 0.52. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.71 by $0.11. The company had revenue of $22.45 billion for the quarter, compared to analysts’ expectations of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business’s revenue was up 4.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.80 EPS. On average, equities analysts forecast that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.11%. The ex-dividend date of this dividend was Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is 30.92%.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. TD Cowen dropped their price target on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, July 18th. The Goldman Sachs Group dropped their price objective on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research note on Friday, July 19th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Monday, September 30th. Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. Finally, Morgan Stanley upped their price objective on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 18th. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $173.43.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.